Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry

JAMA. 2018 Jun 12;319(22):2271-2272. doi: 10.1001/jama.2018.3478.

Authors

Michael S Sinha¹, Gregory D Curfman^{1

2}, Michael A Carrier³

Affiliations

¹ Program On Regulation Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Center for Health Policy and Law, Northeastern University School of Law, Boston, Massachusetts.
³ Rutgers Law School, Rutgers University, Camden, New Jersey.

PMID: 29801104
DOI: 10.1001/jama.2018.3478

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antitrust Laws*
Biosimilar Pharmaceuticals
Drug Costs / legislation & jurisprudence*
Drug Industry / economics
Drug Industry / legislation & jurisprudence*
Drugs, Generic / economics*
Economic Competition / legislation & jurisprudence*
Insurance, Pharmaceutical Services
State Government
United States

Substances

Biosimilar Pharmaceuticals
Drugs, Generic